Fig. 7.

Impaired immune inhibition of AA-MSCs. a–d Compared with HD-MSCs, AA-MSCs showed a defected capacity to inhibit the activation of CD4⁺ and CD8⁺ T cells (HD: n = 5; AA: n = 5). e, f The capacity to inhibit T cells towards Th1 (CD4⁺IFNγ⁺IL4⁻), Th17 (CD4⁺IL4⁻IL17A⁺), and Tc1 (CD8⁺IFNγ⁺IL4⁻) were markedly decreased in AA-MSCs (HD: n = 5; AA: n = 5), while there was no difference in inhibiting T cells into Th2 (CD4⁺IFNγ⁻IL4⁺) and Tc2 (CD8⁺IFNγ⁻IL4⁺) between AA-MSCs and HD-MSCs